Drug Profile
ASCJ 9
Alternative Names: AJ-101; ASC-J9; Dimethyl curcuminLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator AndroScience Corporation
- Class Alkadienes; Antiacnes; Catechols; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acne vulgaris
- Preclinical Male pattern baldness; Wounds; X-linked bulbo-spinal atrophy
Most Recent Events
- 21 Mar 2023 ASCJ 9 is still in preclinical trials for Male pattern baldness, X-linked bulbo-spinal atrophy and Wound in USA (AndroScience pipeline, March 2023)
- 10 Mar 2023 AnnJi Pharmaceutical plans a clinical trial for Alopecia in third quarter of 2024
- 28 Jul 2022 No recent reports of development identified for preclinical development in Male-pattern-baldness in USA (Topical, Foam)